nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—ALB—Auranofin—psoriatic arthritis	0.33	0.387	CbGbCtD
Repaglinide—ALB—Prednisone—psoriatic arthritis	0.105	0.123	CbGbCtD
Repaglinide—SLCO1B1—Methotrexate—psoriatic arthritis	0.0961	0.113	CbGbCtD
Repaglinide—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0543	0.0636	CbGbCtD
Repaglinide—ALB—Methotrexate—psoriatic arthritis	0.0526	0.0617	CbGbCtD
Repaglinide—CYP2C8—Dexamethasone—psoriatic arthritis	0.0506	0.0593	CbGbCtD
Repaglinide—CYP3A4—Triamcinolone—psoriatic arthritis	0.0411	0.0482	CbGbCtD
Repaglinide—CYP3A4—Betamethasone—psoriatic arthritis	0.0353	0.0414	CbGbCtD
Repaglinide—CYP3A4—Prednisolone—psoriatic arthritis	0.0348	0.0408	CbGbCtD
Repaglinide—CYP3A4—Prednisone—psoriatic arthritis	0.0329	0.0386	CbGbCtD
Repaglinide—CYP3A4—Dexamethasone—psoriatic arthritis	0.0205	0.0241	CbGbCtD
Repaglinide—Hepatic enzyme increased—Auranofin—psoriatic arthritis	0.00521	0.0354	CcSEcCtD
Repaglinide—Jaundice—Auranofin—psoriatic arthritis	0.00269	0.0182	CcSEcCtD
Repaglinide—Visual impairment—Auranofin—psoriatic arthritis	0.00238	0.0162	CcSEcCtD
Repaglinide—Eye disorder—Auranofin—psoriatic arthritis	0.00231	0.0157	CcSEcCtD
Repaglinide—Tooth disorder—Triamcinolone—psoriatic arthritis	0.00223	0.0151	CcSEcCtD
Repaglinide—Alopecia—Auranofin—psoriatic arthritis	0.00219	0.0148	CcSEcCtD
Repaglinide—Leukopenia—Auranofin—psoriatic arthritis	0.00193	0.0131	CcSEcCtD
Repaglinide—Thrombocytopenia—Auranofin—psoriatic arthritis	0.00172	0.0117	CcSEcCtD
Repaglinide—Vasculitis—Prednisolone—psoriatic arthritis	0.00161	0.0109	CcSEcCtD
Repaglinide—Dyspepsia—Auranofin—psoriatic arthritis	0.00155	0.0105	CcSEcCtD
Repaglinide—Constipation—Auranofin—psoriatic arthritis	0.0015	0.0102	CcSEcCtD
Repaglinide—Vasculitis—Triamcinolone—psoriatic arthritis	0.00148	0.01	CcSEcCtD
Repaglinide—Vasculitis—Methylprednisolone—psoriatic arthritis	0.00148	0.01	CcSEcCtD
Repaglinide—Gastrointestinal pain—Auranofin—psoriatic arthritis	0.00144	0.00975	CcSEcCtD
Repaglinide—Urticaria—Auranofin—psoriatic arthritis	0.0014	0.00948	CcSEcCtD
Repaglinide—Abdominal pain—Auranofin—psoriatic arthritis	0.00139	0.00943	CcSEcCtD
Repaglinide—Vasculitis—Dexamethasone—psoriatic arthritis	0.00134	0.00911	CcSEcCtD
Repaglinide—Vasculitis—Betamethasone—psoriatic arthritis	0.00134	0.00911	CcSEcCtD
Repaglinide—Cardiac failure congestive—Prednisolone—psoriatic arthritis	0.00126	0.00853	CcSEcCtD
Repaglinide—Pruritus—Auranofin—psoriatic arthritis	0.00124	0.00844	CcSEcCtD
Repaglinide—Visual disturbance—Prednisolone—psoriatic arthritis	0.0012	0.00817	CcSEcCtD
Repaglinide—Diarrhoea—Auranofin—psoriatic arthritis	0.0012	0.00816	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Prednisolone—psoriatic arthritis	0.00118	0.008	CcSEcCtD
Repaglinide—Vasculitis—Prednisone—psoriatic arthritis	0.00117	0.00794	CcSEcCtD
Repaglinide—Cardiac failure congestive—Triamcinolone—psoriatic arthritis	0.00116	0.00785	CcSEcCtD
Repaglinide—Cardiac failure congestive—Methylprednisolone—psoriatic arthritis	0.00115	0.00783	CcSEcCtD
Repaglinide—Vomiting—Auranofin—psoriatic arthritis	0.00112	0.00758	CcSEcCtD
Repaglinide—Rash—Auranofin—psoriatic arthritis	0.00111	0.00752	CcSEcCtD
Repaglinide—Dermatitis—Auranofin—psoriatic arthritis	0.00111	0.00751	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Triamcinolone—psoriatic arthritis	0.00108	0.00735	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Methylprednisolone—psoriatic arthritis	0.00108	0.00734	CcSEcCtD
Repaglinide—Cardiac failure congestive—Dexamethasone—psoriatic arthritis	0.00105	0.00712	CcSEcCtD
Repaglinide—Cardiac failure congestive—Betamethasone—psoriatic arthritis	0.00105	0.00712	CcSEcCtD
Repaglinide—Nausea—Auranofin—psoriatic arthritis	0.00104	0.00709	CcSEcCtD
Repaglinide—Hepatic enzyme increased—Methotrexate—psoriatic arthritis	0.00101	0.00685	CcSEcCtD
Repaglinide—Visual disturbance—Dexamethasone—psoriatic arthritis	0.001	0.00681	CcSEcCtD
Repaglinide—Visual disturbance—Betamethasone—psoriatic arthritis	0.001	0.00681	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Dexamethasone—psoriatic arthritis	0.000983	0.00667	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Betamethasone—psoriatic arthritis	0.000983	0.00667	CcSEcCtD
Repaglinide—Vasculitis—Methotrexate—psoriatic arthritis	0.000978	0.00663	CcSEcCtD
Repaglinide—Pancreatitis—Prednisolone—psoriatic arthritis	0.000967	0.00656	CcSEcCtD
Repaglinide—Cardiac failure congestive—Prednisone—psoriatic arthritis	0.000914	0.0062	CcSEcCtD
Repaglinide—Pancreatitis—Triamcinolone—psoriatic arthritis	0.000889	0.00603	CcSEcCtD
Repaglinide—Pancreatitis—Methylprednisolone—psoriatic arthritis	0.000887	0.00602	CcSEcCtD
Repaglinide—Bronchitis—Triamcinolone—psoriatic arthritis	0.000872	0.00592	CcSEcCtD
Repaglinide—Acute coronary syndrome—Prednisolone—psoriatic arthritis	0.000866	0.00588	CcSEcCtD
Repaglinide—Myocardial infarction—Prednisolone—psoriatic arthritis	0.000862	0.00585	CcSEcCtD
Repaglinide—Acute coronary syndrome—Triamcinolone—psoriatic arthritis	0.000797	0.00541	CcSEcCtD
Repaglinide—Acute coronary syndrome—Methylprednisolone—psoriatic arthritis	0.000795	0.00539	CcSEcCtD
Repaglinide—Myocardial infarction—Triamcinolone—psoriatic arthritis	0.000792	0.00538	CcSEcCtD
Repaglinide—Myocardial infarction—Methylprednisolone—psoriatic arthritis	0.000791	0.00536	CcSEcCtD
Repaglinide—Visual impairment—Prednisolone—psoriatic arthritis	0.00076	0.00516	CcSEcCtD
Repaglinide—Hyperglycaemia—Betamethasone—psoriatic arthritis	0.000742	0.00503	CcSEcCtD
Repaglinide—Hyperglycaemia—Dexamethasone—psoriatic arthritis	0.000742	0.00503	CcSEcCtD
Repaglinide—Visual disturbance—Methotrexate—psoriatic arthritis	0.000731	0.00496	CcSEcCtD
Repaglinide—Rhinitis—Triamcinolone—psoriatic arthritis	0.000727	0.00494	CcSEcCtD
Repaglinide—Rhinitis—Methylprednisolone—psoriatic arthritis	0.000726	0.00492	CcSEcCtD
Repaglinide—Acute coronary syndrome—Dexamethasone—psoriatic arthritis	0.000723	0.00491	CcSEcCtD
Repaglinide—Acute coronary syndrome—Betamethasone—psoriatic arthritis	0.000723	0.00491	CcSEcCtD
Repaglinide—Myocardial infarction—Betamethasone—psoriatic arthritis	0.000719	0.00488	CcSEcCtD
Repaglinide—Myocardial infarction—Dexamethasone—psoriatic arthritis	0.000719	0.00488	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Methotrexate—psoriatic arthritis	0.000716	0.00486	CcSEcCtD
Repaglinide—Arrhythmia—Prednisolone—psoriatic arthritis	0.000705	0.00478	CcSEcCtD
Repaglinide—Pancreatitis—Prednisone—psoriatic arthritis	0.000702	0.00477	CcSEcCtD
Repaglinide—Visual impairment—Methylprednisolone—psoriatic arthritis	0.000698	0.00473	CcSEcCtD
Repaglinide—Erythema—Prednisolone—psoriatic arthritis	0.000687	0.00466	CcSEcCtD
Repaglinide—Eye disorder—Methylprednisolone—psoriatic arthritis	0.000677	0.00459	CcSEcCtD
Repaglinide—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.000672	0.00456	CcSEcCtD
Repaglinide—Immune system disorder—Methylprednisolone—psoriatic arthritis	0.000654	0.00444	CcSEcCtD
Repaglinide—Arrhythmia—Triamcinolone—psoriatic arthritis	0.000648	0.0044	CcSEcCtD
Repaglinide—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.000647	0.00439	CcSEcCtD
Repaglinide—Hyperglycaemia—Prednisone—psoriatic arthritis	0.000646	0.00438	CcSEcCtD
Repaglinide—Visual impairment—Dexamethasone—psoriatic arthritis	0.000635	0.00431	CcSEcCtD
Repaglinide—Visual impairment—Betamethasone—psoriatic arthritis	0.000635	0.00431	CcSEcCtD
Repaglinide—Erythema—Triamcinolone—psoriatic arthritis	0.000632	0.00429	CcSEcCtD
Repaglinide—Malnutrition—Methylprednisolone—psoriatic arthritis	0.00063	0.00428	CcSEcCtD
Repaglinide—Erythema—Methylprednisolone—psoriatic arthritis	0.00063	0.00428	CcSEcCtD
Repaglinide—Acute coronary syndrome—Prednisone—psoriatic arthritis	0.00063	0.00427	CcSEcCtD
Repaglinide—Myocardial infarction—Prednisone—psoriatic arthritis	0.000626	0.00425	CcSEcCtD
Repaglinide—Eye disorder—Betamethasone—psoriatic arthritis	0.000615	0.00417	CcSEcCtD
Repaglinide—Eye disorder—Dexamethasone—psoriatic arthritis	0.000615	0.00417	CcSEcCtD
Repaglinide—Back pain—Triamcinolone—psoriatic arthritis	0.000611	0.00415	CcSEcCtD
Repaglinide—Hypertension—Prednisolone—psoriatic arthritis	0.000593	0.00402	CcSEcCtD
Repaglinide—Arrhythmia—Betamethasone—psoriatic arthritis	0.000588	0.00399	CcSEcCtD
Repaglinide—Arrhythmia—Dexamethasone—psoriatic arthritis	0.000588	0.00399	CcSEcCtD
Repaglinide—Pancreatitis—Methotrexate—psoriatic arthritis	0.000587	0.00398	CcSEcCtD
Repaglinide—Alopecia—Dexamethasone—psoriatic arthritis	0.000582	0.00395	CcSEcCtD
Repaglinide—Alopecia—Betamethasone—psoriatic arthritis	0.000582	0.00395	CcSEcCtD
Repaglinide—Erythema—Dexamethasone—psoriatic arthritis	0.000573	0.00389	CcSEcCtD
Repaglinide—Erythema—Betamethasone—psoriatic arthritis	0.000573	0.00389	CcSEcCtD
Repaglinide—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.000561	0.0038	CcSEcCtD
Repaglinide—Oedema—Prednisolone—psoriatic arthritis	0.000561	0.0038	CcSEcCtD
Repaglinide—Hypertension—Triamcinolone—psoriatic arthritis	0.000545	0.0037	CcSEcCtD
Repaglinide—Hypertension—Methylprednisolone—psoriatic arthritis	0.000544	0.00369	CcSEcCtD
Repaglinide—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000537	0.00364	CcSEcCtD
Repaglinide—Eye disorder—Prednisone—psoriatic arthritis	0.000536	0.00364	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000533	0.00362	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.000529	0.00359	CcSEcCtD
Repaglinide—Immune system disorder—Prednisone—psoriatic arthritis	0.000518	0.00351	CcSEcCtD
Repaglinide—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000516	0.0035	CcSEcCtD
Repaglinide—Oedema—Triamcinolone—psoriatic arthritis	0.000516	0.0035	CcSEcCtD
Repaglinide—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000514	0.00349	CcSEcCtD
Repaglinide—Arrhythmia—Prednisone—psoriatic arthritis	0.000512	0.00348	CcSEcCtD
Repaglinide—Alopecia—Prednisone—psoriatic arthritis	0.000507	0.00344	CcSEcCtD
Repaglinide—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000505	0.00343	CcSEcCtD
Repaglinide—Paraesthesia—Prednisolone—psoriatic arthritis	0.000503	0.00342	CcSEcCtD
Repaglinide—Skin disorder—Methylprednisolone—psoriatic arthritis	0.0005	0.00339	CcSEcCtD
Repaglinide—Erythema—Prednisone—psoriatic arthritis	0.000499	0.00339	CcSEcCtD
Repaglinide—Malnutrition—Prednisone—psoriatic arthritis	0.000499	0.00339	CcSEcCtD
Repaglinide—Hypertension—Betamethasone—psoriatic arthritis	0.000495	0.00336	CcSEcCtD
Repaglinide—Hypertension—Dexamethasone—psoriatic arthritis	0.000495	0.00336	CcSEcCtD
Repaglinide—Hepatitis—Methotrexate—psoriatic arthritis	0.000479	0.00325	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00047	0.00319	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000469	0.00318	CcSEcCtD
Repaglinide—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000468	0.00317	CcSEcCtD
Repaglinide—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000468	0.00317	CcSEcCtD
Repaglinide—Oedema—Betamethasone—psoriatic arthritis	0.000468	0.00317	CcSEcCtD
Repaglinide—Oedema—Dexamethasone—psoriatic arthritis	0.000468	0.00317	CcSEcCtD
Repaglinide—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000463	0.00314	CcSEcCtD
Repaglinide—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000462	0.00313	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—psoriatic arthritis	0.000462	0.00313	CcSEcCtD
Repaglinide—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000458	0.00311	CcSEcCtD
Repaglinide—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000458	0.00311	CcSEcCtD
Repaglinide—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000454	0.00308	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000453	0.00307	CcSEcCtD
Repaglinide—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000453	0.00307	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—psoriatic arthritis	0.000448	0.00304	CcSEcCtD
Repaglinide—Urticaria—Prednisolone—psoriatic arthritis	0.000445	0.00302	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000445	0.00302	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—psoriatic arthritis	0.000433	0.00294	CcSEcCtD
Repaglinide—Hypertension—Prednisone—psoriatic arthritis	0.000431	0.00292	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000426	0.00289	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000426	0.00289	CcSEcCtD
Repaglinide—Arthralgia—Prednisone—psoriatic arthritis	0.000425	0.00288	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—psoriatic arthritis	0.000423	0.00287	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000422	0.00286	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000421	0.00285	CcSEcCtD
Repaglinide—Paraesthesia—Dexamethasone—psoriatic arthritis	0.00042	0.00285	CcSEcCtD
Repaglinide—Paraesthesia—Betamethasone—psoriatic arthritis	0.00042	0.00285	CcSEcCtD
Repaglinide—Erythema—Methotrexate—psoriatic arthritis	0.000417	0.00283	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—psoriatic arthritis	0.000417	0.00283	CcSEcCtD
Repaglinide—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000413	0.0028	CcSEcCtD
Repaglinide—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000412	0.00279	CcSEcCtD
Repaglinide—Dyspepsia—Betamethasone—psoriatic arthritis	0.000412	0.00279	CcSEcCtD
Repaglinide—Urticaria—Triamcinolone—psoriatic arthritis	0.00041	0.00278	CcSEcCtD
Repaglinide—Urticaria—Methylprednisolone—psoriatic arthritis	0.000409	0.00277	CcSEcCtD
Repaglinide—Oedema—Prednisone—psoriatic arthritis	0.000407	0.00276	CcSEcCtD
Repaglinide—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000407	0.00276	CcSEcCtD
Repaglinide—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000407	0.00276	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000404	0.00274	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000404	0.00274	CcSEcCtD
Repaglinide—Back pain—Methotrexate—psoriatic arthritis	0.000404	0.00274	CcSEcCtD
Repaglinide—Skin disorder—Prednisone—psoriatic arthritis	0.000396	0.00268	CcSEcCtD
Repaglinide—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000383	0.0026	CcSEcCtD
Repaglinide—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000383	0.0026	CcSEcCtD
Repaglinide—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00038	0.00258	CcSEcCtD
Repaglinide—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000379	0.00257	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—psoriatic arthritis	0.000373	0.00253	CcSEcCtD
Repaglinide—Urticaria—Betamethasone—psoriatic arthritis	0.000372	0.00252	CcSEcCtD
Repaglinide—Urticaria—Dexamethasone—psoriatic arthritis	0.000372	0.00252	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000371	0.00252	CcSEcCtD
Repaglinide—Abdominal pain—Betamethasone—psoriatic arthritis	0.00037	0.00251	CcSEcCtD
Repaglinide—Abdominal pain—Dexamethasone—psoriatic arthritis	0.00037	0.00251	CcSEcCtD
Repaglinide—Paraesthesia—Prednisone—psoriatic arthritis	0.000366	0.00248	CcSEcCtD
Repaglinide—Pruritus—Triamcinolone—psoriatic arthritis	0.000365	0.00247	CcSEcCtD
Repaglinide—Pruritus—Methylprednisolone—psoriatic arthritis	0.000364	0.00247	CcSEcCtD
Repaglinide—Dyspepsia—Prednisone—psoriatic arthritis	0.000359	0.00243	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—psoriatic arthritis	0.000355	0.00241	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—psoriatic arthritis	0.000355	0.00241	CcSEcCtD
Repaglinide—Rash—Prednisolone—psoriatic arthritis	0.000353	0.0024	CcSEcCtD
Repaglinide—Dermatitis—Prednisolone—psoriatic arthritis	0.000353	0.0024	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000353	0.00239	CcSEcCtD
Repaglinide—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000352	0.00239	CcSEcCtD
Repaglinide—Headache—Prednisolone—psoriatic arthritis	0.000351	0.00238	CcSEcCtD
Repaglinide—Constipation—Prednisone—psoriatic arthritis	0.000348	0.00236	CcSEcCtD
Repaglinide—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00034	0.00231	CcSEcCtD
Repaglinide—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000333	0.00226	CcSEcCtD
Repaglinide—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000333	0.00226	CcSEcCtD
Repaglinide—Nausea—Prednisolone—psoriatic arthritis	0.000333	0.00226	CcSEcCtD
Repaglinide—Pruritus—Dexamethasone—psoriatic arthritis	0.000331	0.00225	CcSEcCtD
Repaglinide—Pruritus—Betamethasone—psoriatic arthritis	0.000331	0.00225	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—psoriatic arthritis	0.000331	0.00224	CcSEcCtD
Repaglinide—Vomiting—Triamcinolone—psoriatic arthritis	0.000328	0.00222	CcSEcCtD
Repaglinide—Vomiting—Methylprednisolone—psoriatic arthritis	0.000327	0.00222	CcSEcCtD
Repaglinide—Rash—Triamcinolone—psoriatic arthritis	0.000325	0.00221	CcSEcCtD
Repaglinide—Dermatitis—Triamcinolone—psoriatic arthritis	0.000325	0.0022	CcSEcCtD
Repaglinide—Rash—Methylprednisolone—psoriatic arthritis	0.000324	0.0022	CcSEcCtD
Repaglinide—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000324	0.0022	CcSEcCtD
Repaglinide—Urticaria—Prednisone—psoriatic arthritis	0.000324	0.0022	CcSEcCtD
Repaglinide—Headache—Triamcinolone—psoriatic arthritis	0.000323	0.00219	CcSEcCtD
Repaglinide—Headache—Methylprednisolone—psoriatic arthritis	0.000322	0.00219	CcSEcCtD
Repaglinide—Abdominal pain—Prednisone—psoriatic arthritis	0.000322	0.00218	CcSEcCtD
Repaglinide—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00032	0.00217	CcSEcCtD
Repaglinide—Diarrhoea—Betamethasone—psoriatic arthritis	0.00032	0.00217	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.00031	0.0021	CcSEcCtD
Repaglinide—Nausea—Triamcinolone—psoriatic arthritis	0.000306	0.00208	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—psoriatic arthritis	0.000306	0.00207	CcSEcCtD
Repaglinide—Nausea—Methylprednisolone—psoriatic arthritis	0.000306	0.00207	CcSEcCtD
Repaglinide—Hypersensitivity—Prednisone—psoriatic arthritis	0.0003	0.00204	CcSEcCtD
Repaglinide—Dyspepsia—Methotrexate—psoriatic arthritis	0.0003	0.00203	CcSEcCtD
Repaglinide—Vomiting—Betamethasone—psoriatic arthritis	0.000297	0.00202	CcSEcCtD
Repaglinide—Vomiting—Dexamethasone—psoriatic arthritis	0.000297	0.00202	CcSEcCtD
Repaglinide—Rash—Betamethasone—psoriatic arthritis	0.000295	0.002	CcSEcCtD
Repaglinide—Rash—Dexamethasone—psoriatic arthritis	0.000295	0.002	CcSEcCtD
Repaglinide—Dermatitis—Dexamethasone—psoriatic arthritis	0.000295	0.002	CcSEcCtD
Repaglinide—Dermatitis—Betamethasone—psoriatic arthritis	0.000295	0.002	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000294	0.00199	CcSEcCtD
Repaglinide—Headache—Dexamethasone—psoriatic arthritis	0.000293	0.00199	CcSEcCtD
Repaglinide—Headache—Betamethasone—psoriatic arthritis	0.000293	0.00199	CcSEcCtD
Repaglinide—Pruritus—Prednisone—psoriatic arthritis	0.000288	0.00196	CcSEcCtD
Repaglinide—Diarrhoea—Prednisone—psoriatic arthritis	0.000279	0.00189	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000278	0.00189	CcSEcCtD
Repaglinide—Nausea—Dexamethasone—psoriatic arthritis	0.000278	0.00189	CcSEcCtD
Repaglinide—Nausea—Betamethasone—psoriatic arthritis	0.000278	0.00189	CcSEcCtD
Repaglinide—Urticaria—Methotrexate—psoriatic arthritis	0.00027	0.00184	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—psoriatic arthritis	0.000269	0.00183	CcSEcCtD
Repaglinide—Vomiting—Prednisone—psoriatic arthritis	0.000259	0.00176	CcSEcCtD
Repaglinide—Rash—Prednisone—psoriatic arthritis	0.000257	0.00174	CcSEcCtD
Repaglinide—Dermatitis—Prednisone—psoriatic arthritis	0.000257	0.00174	CcSEcCtD
Repaglinide—Headache—Prednisone—psoriatic arthritis	0.000255	0.00173	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000251	0.0017	CcSEcCtD
Repaglinide—Nausea—Prednisone—psoriatic arthritis	0.000242	0.00164	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—psoriatic arthritis	0.000241	0.00163	CcSEcCtD
Repaglinide—Diarrhoea—Methotrexate—psoriatic arthritis	0.000233	0.00158	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—psoriatic arthritis	0.000216	0.00147	CcSEcCtD
Repaglinide—Rash—Methotrexate—psoriatic arthritis	0.000215	0.00146	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—psoriatic arthritis	0.000214	0.00146	CcSEcCtD
Repaglinide—Headache—Methotrexate—psoriatic arthritis	0.000213	0.00145	CcSEcCtD
Repaglinide—Nausea—Methotrexate—psoriatic arthritis	0.000202	0.00137	CcSEcCtD
